Amber Therapeutics’ Series A: Behind the $100M Raise
Amber Therapeutics’ Series A wasn’t just a headline—it was a milestone. In one of the largest European Series A medtech financings to date, the company raised $100M to advance its closed-loop neuromodulation therapy for mixed urinary incontinence. But this wasn’t just a story of capital; it was a story of timing, trust, team-building, and a smart pivot in development strategy that united top-tier financial and strategic investors.
Originally published here: https://tinyurl.com/u3ejnbfa


